Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma

Table 1 Patient characteristics before and after propensity score matching

Characteristic		Before PSM			After PSM
		TACE + L	TACE + SL	P value	TACE + L	TACE + SL	P value
Gender				1.00			1.00
	Female	3	3		2	1
	Male	24	27		13	14
Age (year)				0.66			1.00
	≥ 60	16	15		8	8
	< 60	11	15		7	7
ECOG				1.00			0.43
	0	7	8		3	6
	1	20	22		12	9
Etiology				0.49			0.65
	HBV	22	21		13	11
	Other	5	9		2	4
Cirrhosis				1.00			1.00
	No	4	4		2	2
	Yes	23	26		13	13
Tumor number				0.35			0.71
	≥ 3	11	17		6	8
	< 3	16	13		9	7
Tumor size (cm)				0.43			1.00
	≥ 7	8	13		4	5
	< 7	19	17		11	10
PVTT				0.05			1.00
	No	22	16		11	11
	Yes	5	14		4	4
Metastases				1.00			0.33
	No	23	26		11	14
	Yes	4	4		4	1
BCLC				0.03			1.00
	B	22	15		11	11
	C	5	15		4	4
Child-Pugh class				1.00			1.00
	A	25	27		14	15
	B	2	3		1	0
AFP (ng/mL)				0.00			1.00
	≥ 100	2	17		2	2
	< 100	25	13		13	13

PSM: Propensity score matching; TACE + L: Transarterial chemoembolization with lenvatinib alone; TACE + SL: Transarterial chemoembolization combined with lenvatinib and sintilimab; ECOG: Eastern Cooperative Oncology Group; PVTT: Portal vein tumour thrombosis; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus.